Could a diabetes pill boost breast cancer treatment? new study explores link between insulin and chemo
NCT ID NCT05989347
First seen May 27, 2026 · Last updated Jun 16, 2026 · Updated 4 times
Summary
This early-phase study is testing whether adding dapagliflozin, a diabetes drug, to standard chemotherapy can improve insulin resistance in women with early-stage HER2-negative breast cancer who have high insulin levels. About 20 participants will receive the drug alongside chemo to see how it affects metabolic markers. The goal is to gather safety and biomarker data, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale Cancer Center Smilow Cancer Hospital
RECRUITINGNew Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.